Cargando…

Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review

The coronavirus disease of 2019 (COVID-19) has caused significant morbidity and mortality among infected individuals across the world. High transmissibility rate of the causative virus – Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) – has led to immense strain and bottlenecking of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Srinivasan, Kritika, Rao, Mana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646822/ https://www.ncbi.nlm.nih.gov/pubmed/34881025 http://dx.doi.org/10.1177/20499361211063016

Ejemplares similares

Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis
por: Yamada, Kentaro, et al.
Publicado: (2016)

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
por: FURUTA, Yousuke, et al.
Publicado: (2017)

T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections
por: Furuta, Yousuke, et al.
Publicado: (2009)

Favipiravir (T-705) protects against Nipah virus infection in the hamster model
por: Dawes, Brian E., et al.
Publicado: (2018)

Favipiravir-induced Liver Injury in Patients with Coronavirus Disease 2019
por: Kumar, Pramod, et al.
Publicado: (2021)

Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus
por: Tani, Hideki, et al.
Publicado: (2016)

Effective Oral Favipiravir (T-705) Therapy Initiated after the Onset of Clinical Disease in a Model of Arenavirus Hemorrhagic Fever
por: Mendenhall, Michelle, et al.
Publicado: (2011)

Severe fever with thrombocytopenia syndrome (SFTS) treated with a novel antiviral medication, favipiravir (T-705)
por: Song, Rui, et al.
Publicado: (2019)

Use of Favipiravir for the Treatment of Coronavirus Disease 2019 in the Setting of Hospitel
por: Surapat, Bhitta, et al.
Publicado: (2022)

Favipiravir (T-705) Protects IFNAR(−/−) Mice against Lethal Zika Virus Infection in a Sex-Dependent Manner
por: Matz, Keesha, et al.
Publicado: (2021)

Evaluation of Antiviral Efficacy of Ribavirin, Arbidol, and T-705 (Favipiravir) in a Mouse Model for Crimean-Congo Hemorrhagic Fever
por: Oestereich, Lisa, et al.
Publicado: (2014)

Broad Spectrum Antiviral Activity of Favipiravir (T-705): Protection from Highly Lethal Inhalational Rift Valley Fever
por: Caroline, Amy L., et al.
Publicado: (2014)

Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019
por: Hase, Ryota, et al.
Publicado: (2020)

The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019
por: Çap, Murat, et al.
Publicado: (2020)

Favipiravir (T-705) Inhibits Junín Virus Infection and Reduces Mortality in a Guinea Pig Model of Argentine Hemorrhagic Fever
por: Gowen, Brian B., et al.
Publicado: (2013)

Poxvirus-driven human diseases and emerging therapeutics
por: Srinivasan Rajsri, Kritika, et al.
Publicado: (2022)

Favipiravir-induced fever in coronavirus disease 2019: A report of two cases
por: Takoi, Hiroyuki, et al.
Publicado: (2020)

The Ambiguous Base-Pairing and High Substrate Efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-Triphosphate towards Influenza A Virus Polymerase
por: Jin, Zhinan, et al.
Publicado: (2013)

Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza
por: Wang, Yeming, et al.
Publicado: (2020)

Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study
por: Alattar, Rand A., et al.
Publicado: (2022)

508. Title Favipiravir for the Treatment of Coronavirus Disease 2019; A Propensity Score Matched Cohort Study
por: Alattar, Rand A, et al.
Publicado: (2021)

Favipiravir-based regimen for coronavirus disease 2019 pneumonia for a 47-day-old male newborn
por: Moolasart, Visal, et al.
Publicado: (2020)

Evaluation of minocycline combined with favipiravir therapy in coronavirus disease 2019 patients: A case-series study
por: Itoh, Kazuhiro, et al.
Publicado: (2022)

Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019
por: Koshi, Eri, et al.
Publicado: (2020)

An evaluation of the Hitachi 705 analyser
por: Ferré, C., et al.
Publicado: (1984)

Dalcetrapib: JTT 705; JTT-705; R 1658; R1658; RG1658; RO 4607381; RO4607381
Publicado: (2012)

Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients
por: Prakash, Ajay, et al.
Publicado: (2020)

Favipiravir in Therapy of Viral Infections
por: Łagocka, Ryta, et al.
Publicado: (2021)

Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
por: Holubar, Marisa, et al.
Publicado: (2022)

Serial computed tomography findings of Coronavirus disease 2019 (COVID-19) pneumonia treated with favipiravir and steroid therapy: report of 11 cases
por: Irizato, Naoki, et al.
Publicado: (2021)

Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19
por: Ison, Michael G., et al.
Publicado: (2021)

Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19)
por: Jiang, Fang, et al.
Publicado: (2020)

Clinical Utility of Circulating Pentraxin 3 as a Prognostic Biomarker in Coronavirus Disease 2019: A Systematic Review and Meta-analysis
por: Ke, Yani, et al.
Publicado: (2022)

Averages of Weight and Chest Measurements of 705 Madras Coolies
por: Nicol, Burton
Publicado: (1911)

705 Evaluation of Invasive Fungal Infections in the Burn ICU
por: Pournezhad, Sam, et al.
Publicado: (2023)

Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series
por: Koba, Hayato, et al.
Publicado: (2020)

Clinical effect and antiviral mechanism of T-705 in treating severe fever with thrombocytopenia syndrome
por: Li, Hao, et al.
Publicado: (2021)

Role of favipiravir in the treatment of COVID-19
por: Joshi, Shashank, et al.
Publicado: (2021)

Multi-organ system involvement in coronavirus disease 2019 (COVID-19): A mega review
por: Moslehi, Naghmeh, et al.
Publicado: (2022)

Turbidimetric analysis on the Hitachi 705 using orosomucoid as a model
por: Legg, E. F., et al.
Publicado: (1984)

Cannot write session to /tmp/vufind_sessions/sess_ofh1o8gmpf85m1j4ltep3m2mja